Global Upfront Newspapers
Canada Health News

Medicago reports promising but preliminary results of possible COVID-19 vaccine

Interim results of a Phase 1 clinical trial based on two doses

The Canadian Press, November 10, 2020

A volunteer participates in Medicago’s Phase 1 clinical trial for its COVID-19 vaccine candidate in Quebec City. (CNW Group/Medicago)

Canadian drug developer Medicago said Tuesday it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company said interim results of a Phase 1 clinical trial found all subjects developed “a promising antibody response after two doses” of its COVID-19 vaccine candidate.

Phase 1 clinical trials include about 100 volunteers and are designed to flag any immediate safety concerns and offer an initial indication of whether the shots produce an immune response.

Medicago did not disclose full safety data and said the side effects were generally mild to moderate and short in duration. The company posted the results on a preprint server and still need to be peer reviewed by independent experts to check its validity. 

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people aged 18-55.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its plant-based COVID-19 vaccine candidate, subject to regulatory approval.

World needs many vaccine suppliers, CEO says

The company said it planned to use a lower-dose version of its vaccine, along with GlaxoSmithKline’s adjuvant — a compound that enhances the body’s immune response.

The federal government has signed a deal with Medicago to secure the rights to buy 76 million doses of its vaccine. Medicago will also receive $173 million in funding from Ottawa for its vaccine research and development and for the construction of its Quebec City manufacturing facility.

Medicago’s chief executive officer, Bruce Clark, said the company is in talks with several other countries for potential deals.

“Even if you add the total number of doses that have been committed [by other companies,] you are looking at a global population of seven billion and it will require different suppliers,” Clark told Reuters.

Medicago is Canada’s most advanced domestic COVID-19 vaccine project but lags behind larger, global rivals such as Pfizer, AstraZeneca and Johnson & Johnson, which have begun late-stage trials.

On Monday, Pfizer said initial data from its large-scale trial on more than 43,000 volunteers suggested its vaccine was more than 90 per cent effective.

Pfizer’s study has not been peer reviewed, safety data hasn’t been released and infectious disease physicians say key questions such as how well the vaccine works in blocking transmission, how long it protects and who it protects still need to be answered.

With files from CBC News and Reuters

Advertize With Us

See Also

South African Firm Multichoice In Trouble As Nigerian Senate Constitutes 7-man Adhoc Committee To Probe Pay-TV Tariff Hike  

Global Upfront

Former CDS, Service Chiefs, Chief of Defence Intelligence now Ambassadors-Designate as Buhari forwards names to Senate

Global Upfront

‘You’re Seventh Time Aspirant’ With History Of ‘Corruption Promoting And Vote-buying Mercenaries,’ Obi’s Group Mocks Atiku

Global Upfront

Nigeria records triple jump in COVID-19 cases on Monday, from 55 to 167

Global Upfront

1,178 lives lost as Cholera spreads to 23 States in Nigeria

Global Upfront

Arotile, Nigeria’s first female combat helicopter pilot buried in Abuja

Global Upfront

Nigeria’s CDS General Irabor Fumes Over Governor Matawalle’s Order For Citizens To Arm For Self-defence

Global Upfront

Nollywood Actress Ada Ameh Laid To Rest In Ogobia Benue State Hometown

Global Upfront

U.S. Politics: Trump Invites Putin, Begs Him To Help Release Dirt On Hunter Biden, President Joe Biden’s Son

Global Upfront

FG Launch National Animal Identification and Traceability System To Curb Rustling And Improve Livestock Business

Global Upfront

This website uses Cookies to improve User experience. We assume this is OK...If not, please opt-out! Accept Read More